ELSTREE, England and DURHAM, N.C., May 23, 2018 /PRNewswire/ — Bio Products Laboratory Limited (BPL), a leading manufacturer of plasma-derived protein therapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (BLA) for Coagadex® (Coagulation Factor X, Human) for prophylactic treatment of hereditary factor X …